BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26761210)

  • 1. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
    Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD
    Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
    Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
    Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
    Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
    Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
    Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
    Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.
    Zhang W; Pang Q; Zhang X; Yan C; Wang Q; Yang J; Yu S; Liu X; Pan Y; Yuan Z; Wang P; Xiao Z
    Cancer Sci; 2017 Apr; 108(4):590-597. PubMed ID: 28192623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
    Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
    Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
    Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y
    Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
    Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
    Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
    García-Díez I; Hernández-Ruiz E; Andrades E; Gimeno J; Ferrándiz-Pulido C; Yébenes M; García-Patos V; Pujol RM; Hernández-Muñoz I; Toll A
    Am J Dermatopathol; 2018 Sep; 40(9):647-654. PubMed ID: 29742559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus.
    Chen MF; Chen PT; Lu MS; Lin PY; Chen WC; Lee KD
    Mol Cancer; 2013 Apr; 12():26. PubMed ID: 23561329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.